Morphologic Blooming in Breast MRI As a Characterization of Margin for Discriminating Benign from Malignant Lesions

Overview

Journal Acad Radiol

Specialty Radiology

Date 2006 Oct 31

PMID 17070452

Citations 10

Authors

Alan Penn

Scott Thompson

Rachel Brem

Constance Lehman

Paul Weatherall

Mitchell Schnall

Gillian Newstead

Emily Conant

Susan Ascher

Elizabeth Morris

Etta Pisano

Affiliations

Soon will be listed here.

Abstract

Rationale And Objectives: Develop a fully automated, objective method for evaluating morphology on breast magnetic resonance (MR) images and evaluate effectiveness of the new morphologic method for detecting breast cancers.

Materials And Methods: We present a new automated method (morphologic blooming) for identifying and classifying breast lesions on MR that measures margin sharpness, a characteristic related to blooming, defined as rapid enhancement, with a border that is initially sharp but becomes unsharp after 7 minutes. Independent training sets (98 biopsy-proven lesions) and testing sets (179 breasts, 127 patients, acquired at five institutions) were used. Morphologic blooming was evaluated as a stand-alone feature and as an adjunct to kinetics using free-response receiver operating characteristic and sensitivity analysis. Dependence of false-positive (FP) rates on acquisition times and pathologies of contralateral breasts were evaluated.

Results: Sensitivity of morphologic blooming was 80% with 2.46 FP per noncancerous breast: FPs did not vary significantly by acquisition times. FPs varied significantly by pathologies of contralateral breasts (cancerous contralateral: 4.29 FP/breast; noncancerous contralateral: 0.48 FP/breast; P < .0001). Evaluation of 45 cancers showed suspicious morphologies on 10/15 (67%) cancers with benign-like kinetics and suspicious kinetics on 5/10 (50%) cancers with benign-like morphologies.

Conclusion: We present a new, fully automated method of identifying and classifying margin sharpness of breast lesions on MR that can be used to direct radiologists' attention to lesions with suspicious morphologies. Morphologic blooming may have important utility for assisting radiologists in identifying cancers with benign-like kinetics and discriminating normal tissues that exhibit cancer-like enhancement curves and for improving the performance of computer-aided detection systems.

Citing Articles

Discrimination of benign from malignant breast lesions in dense breasts with model-based analysis of regions-of-interest using directional diffusion-weighted images.

Penn A, Medved M, Dialani V, Pisano E, Cole E, Brousseau D BMC Med Imaging. 2020; 20(1):61.

PMID: 32517657 PMC: 7282088. DOI: 10.1186/s12880-020-00458-3.

Using quantitative features extracted from T2-weighted MRI to improve breast MRI computer-aided diagnosis (CAD).

Gallego-Ortiz C, Martel A PLoS One. 2017; 12(11):e0187501.

PMID: 29112948 PMC: 5675400. DOI: 10.1371/journal.pone.0187501.

Pattern identification of biomedical images with time series: Contrasting THz pulse imaging with DCE-MRIs.

Yin X, Hadjiloucas S, Zhang Y, Su M, Miao Y, Abbott D Artif Intell Med. 2016; 67:1-23.

PMID: 26951630 PMC: 6684234. DOI: 10.1016/j.artmed.2016.01.005.

Potential of computer-aided diagnosis of high spectral and spatial resolution (HiSS) MRI in the classification of breast lesions.

Bhooshan N, Giger M, Medved M, Li H, Wood A, Yuan Y J Magn Reson Imaging. 2013; 39(1):59-67.

PMID: 24023011 PMC: 4143529. DOI: 10.1002/jmri.24145.

Comparing post-operative human breast specimen radiograph and MRI in lesion margin and volume assessment.

Abe H, Shimauchi A, Fan X, River J, Sattar H, Mueller J J Appl Clin Med Phys. 2012; 13(6):3802.

PMID: 23149773 PMC: 5718530. DOI: 10.1120/jacmp.v13i6.3802.

References

Wood C . Computer Aided Detection (CAD) for breast MRI. Technol Cancer Res Treat. 2005; 4(1):49-53. DOI: 10.1177/153303460500400107. View

Bluemke D, Gatsonis C, Chen M, DeAngelis G, DeBruhl N, Harms S . Magnetic resonance imaging of the breast prior to biopsy. JAMA. 2004; 292(22):2735-42. DOI: 10.1001/jama.292.22.2735. View

Kitagawa K, Sakuma H, Ishida N, Hirano T, Ishihara A, Takeda K . Contrast-enhanced high-resolution MRI of invasive breast cancer: correlation with histopathologic subtypes. AJR Am J Roentgenol. 2004; 183(6):1805-9. DOI: 10.2214/ajr.183.6.01831805. View

Kuhl C, Mielcareck P, Klaschik S, Leutner C, Wardelmann E, Gieseke J . Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions?. Radiology. 1999; 211(1):101-10. DOI: 10.1148/radiology.211.1.r99ap38101. View

Gilhuijs K, Giger M, Bick U . Computerized analysis of breast lesions in three dimensions using dynamic magnetic-resonance imaging. Med Phys. 1998; 25(9):1647-54. DOI: 10.1118/1.598345. View

Mussurakis S, Buckley D, Coady A, Turnbull L, Horsman A . Observer variability in the interpretation of contrast enhanced MRI of the breast. Br J Radiol. 1996; 69(827):1009-16. DOI: 10.1259/0007-1285-69-827-1009. View

Pohlman S, Powell K, Obuchowski N, Chilcote W . Quantitative classification of breast tumors in digitized mammograms. Med Phys. 1996; 23(8):1337-45. DOI: 10.1118/1.597707. View

Landis J, Koch G . The measurement of observer agreement for categorical data. Biometrics. 1977; 33(1):159-74. View

Thibault F, Nos C, Meunier M, El Khoury C, Ollivier L, Sigal-Zafrani B . MRI for surgical planning in patients with breast cancer who undergo preoperative chemotherapy. AJR Am J Roentgenol. 2004; 183(4):1159-68. DOI: 10.2214/ajr.183.4.1831159. View

10.

Sardanelli F, Giuseppetti G, Panizza P, Bazzocchi M, Fausto A, Simonetti G . Sensitivity of MRI versus mammography for detecting foci of multifocal, multicentric breast cancer in Fatty and dense breasts using the whole-breast pathologic examination as a gold standard. AJR Am J Roentgenol. 2004; 183(4):1149-57. DOI: 10.2214/ajr.183.4.1831149. View

11.

Chakraborty D, Berbaum K . Observer studies involving detection and localization: modeling, analysis, and validation. Med Phys. 2004; 31(8):2313-30. DOI: 10.1118/1.1769352. View

12.

Warner E, Plewes D, Hill K, Causer P, Zubovits J, Jong R . Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004; 292(11):1317-25. DOI: 10.1001/jama.292.11.1317. View

13.

Kriege M, Brekelmans C, Boetes C, Besnard P, Zonderland H, Obdeijn I . Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004; 351(5):427-37. DOI: 10.1056/NEJMoa031759. View

14.

Chen W, Giger M, Lan L, Bick U . Computerized interpretation of breast MRI: investigation of enhancement-variance dynamics. Med Phys. 2004; 31(5):1076-82. DOI: 10.1118/1.1695652. View

15.

Fischer D, Baltzer P, Malich A, Wurdinger S, Freesmeyer M, Marx C . Is the "blooming sign" a promising additional tool to determine malignancy in MR mammography?. Eur Radiol. 2003; 14(3):394-401. DOI: 10.1007/s00330-003-2055-9. View

16.

Szabo B, Aspelin P, Wiberg M, Bone B . Dynamic MR imaging of the breast. Analysis of kinetic and morphologic diagnostic criteria. Acta Radiol. 2003; 44(4):379-86. DOI: 10.1080/j.1600-0455.2003.00084.x. View

17.

Neubauer H, Li M, Kuehne-Heid R, Schneider A, Kaiser W . High grade and non-high grade ductal carcinoma in situ on dynamic MR mammography: characteristic findings for signal increase and morphological pattern of enhancement. Br J Radiol. 2003; 76(901):3-12. DOI: 10.1259/bjr/14883856. View

18.

Gilhuijs K, Deurloo E, Muller S, Peterse J, Schultze Kool L . Breast MR imaging in women at increased lifetime risk of breast cancer: clinical system for computerized assessment of breast lesions initial results. Radiology. 2002; 225(3):907-16. DOI: 10.1148/radiol.2253011582. View

19.

Kelcz F, Furman-Haran E, Grobgeld D, Degani H . Clinical testing of high-spatial-resolution parametric contrast-enhanced MR imaging of the breast. AJR Am J Roentgenol. 2002; 179(6):1485-92. DOI: 10.2214/ajr.179.6.1791485. View

20.

Morrow M, Strom E, Bassett L, Dershaw D, Fowble B, Harris J . Standard for the management of ductal carcinoma in situ of the breast (DCIS). CA Cancer J Clin. 2002; 52(5):256-76. DOI: 10.3322/canjclin.52.5.256. View